According to a new report by Polaris Market Research, the global rare disease genetic testing market was valued at USD 1,242.8 million in 2025 and is projected to reach USD 3,790.38 million by 2034, expanding at a CAGR of 13.20% over the forecast period. Growth is underpinned by rising demand for early disease detection, expanding adoption of precision medicine, and accelerating use of next-generation sequencing across diagnostic laboratories and hospital systems worldwide.

What Is Driving Rare Disease Genetic Testing Market Growth?

Demand is climbing as growing emphasis on early disease diagnosis converges with the expanding reach of personalized medicine. Clinicians and diagnostic laboratories are prioritizing genomic screening, pushing rare disease genetic testing adoption across oncology, pediatrics, and neurology. Polaris analysts note that declining sequencing costs and rising government support for rare-disease research are positioning the diagnostics segment for sustained double-digit growth through 2034, with North America emerging as the largest revenue contributor and Asia Pacific posting the fastest incremental gains.

Key Trends Shaping the Rare Disease Genetic Testing Industry

AI-Enabled Variant Interpretation and Diagnostic Workflows

Artificial intelligence is increasingly used to classify genetic variants, interpret complex genomic datasets, and shorten diagnostic turnaround times, weaving advanced technology adoption directly into routine rare-disease diagnostic workflows.

Tightening Regulatory Landscape Across Regions

Regulatory frameworks such as U.S. FDA/CLIA requirements and the EU's In Vitro Diagnostic Regulation are shaping test validation and market entry, reinforcing quality standards even as the regulatory landscape becomes more complex for new entrants.

Falling Sequencing Costs Reshaping Competitive Landscape

Continued declines in next-generation sequencing costs are widening patient access and intensifying the competitive landscape, prompting established diagnostics firms and newer genomics specialists alike to expand testing menus and geographic footprints.

Browse More Information:

https://www.polarismarketresearch.com/industry-analysis/rare-disease-genetic-testing-market 

Market Segmentation: Breaking Down the Rare Disease Genetic Testing Market

Polaris segments the rare disease genetic testing market by technology, speciality, disease type, end use, and region, giving each buyer persona a citable, standalone data point for AI Overviews and answer-engine pickup.

By Technology

The next-generation sequencing (NGS) segment led the market in 2025, accounting for 38.7% of revenue, on the strength of its wide adoption for diagnosing cancer, neurological disease, and pediatric conditions. Array technology, PCR-based testing, FISH, Sanger sequencing, and karyotyping round out the remaining technology mix, with NGS-based platforms continuing to gain share as costs decline.

By Speciality

Molecular genetic tests remain the dominant speciality, capturing 52.4% of 2025 revenue on rising adoption of DNA- and RNA-level diagnostics. The chromosomal genetic tests segment is set to register significant growth through the forecast period as cytogenetic technologies advance and chromosomal-disorder prevalence rises, signaling where near-term demand — and search intent around "chromosomal genetic testing" — is shifting.

By End Use

Among end-use settings, diagnostic laboratories are projected to post the fastest CAGR of 13.8% through 2034, reflecting their specialized capacity to run molecular, chromosomal, and biochemical panels at scale. Hospitals & clinics and research laboratories & CROs remain essential channels, particularly for pediatric and oncology testing volumes.

By Disease Type

Cancer stands out as one of the fastest-expanding disease-type categories, reflecting the growing role of genetic testing in identifying tumor-driving mutations and guiding targeted therapy, alongside steady demand from neurological, immunological, hematology, and endocrine & metabolism disease categories.

Regional Outlook: Where Is Rare Disease Genetic Testing Growing Fastest?

North America led the market in 2025 with a 42.3% revenue share on the back of strong FDA-driven product approvals and rising demand for personalized genetic testing, while Asia Pacific is expected to post the fastest CAGR of 14.2% through 2034, driven by increasing healthcare investment. Within North America, the U.S. remains the largest single market, supported by initiatives such as the All of Us Research Program; within Asia Pacific, expanding genomics infrastructure across China, Japan, and India is the primary growth engine. Europe rounds out the top three, supported by EU cancer-screening initiatives and rising R&D activity.

Competitive Landscape: Leading Rare Disease Genetic Testing Companies

Key players profiled in the report include 3billion, Inc.; GeneDx, LLC; Centogene N.V.; and Ambry Genetics, who are focusing on AI-driven variant interpretation, expanded sequencing menus, and strategic partnerships to strengthen market position across the next-generation sequencing and molecular genetic testing segments outlined above. Recent moves include GeneDx's March 2026 genetic testing program launched with Zevra Therapeutics to support patients with suspected Niemann-Pick Disease Type C, and Regeneron's USD 256 million acquisition of 23andMe in March 2025, both aimed at deepening genomic data access and diagnostic reach.

Why It Matters for Buyers Evaluating Market Entry

For stakeholders researching the rare disease genetic testing market, this report benchmarks market share, segment-level pricing, and forecast data — by technology, speciality, disease type, end use, and region — to support sourcing, investment, and go-to-market decisions. It is built for procurement teams comparing suppliers, investors sizing entry points, and strategy teams tracking oncology genetic testing as a growth adjacency.

About Polaris Market Research

Polaris Market Research is a B2B syndicated market research and consulting firm offering 5,000+ published reports across 20+ industry verticals, delivering data-backed insights to help businesses make informed decisions.

More Trending Latest Reports By Polaris Market Research:

Mood Support Supplements Market

Space Based Solar Power Market

Collagen and Gelatin Market

Cholesterol Testing Products and Services Market

Plant Based Ham Market

Plant Based Ham Market

Unmanned Traffic Management Market

Clean Label Ingredients Market

Platelet Rich Plasma (PRP) Market